Managing Neuromyelitis Optica Spectrum Disorders: How Can You Achieve Long-Term Relapse-Free Outcomes in Practice?
Podcast 3
Post-Test/Evaluation

Questions marked with a * are required

18%

Contact Information

First Name

Last Name

Email Address

Credentials/Degree (MD, DO, RN, etc.)

Date of Participation

Which of the following is true regarding attack prevention in optimizing disease outcomes for patients with NMOSD?

A. Preventing attacks will stop the accrual of disability in patients with NMOSD

B. Preventing attacks will not affect disability in patients with NMOSD

C. Preventing attacks will lead to a poor prognosis for patients with NMOSD

D. Preventing attacks will increase inflammation in patients with NMOSD

A 26-year-old woman presents with right optic neuropathy with good recovery. She has a history of type 1 diabetes and is currently on insulin. She was diagnosed with NMOSD and was found to be AQP4 positive. Being a newly diagnosed patient with NMOSD and AQP4 positive, what are the important considerations for selecting an FDA-approved therapy?

A. Efficacy and safety of each treatment

B. Selecting biomarkers that will predict treatment outcomes

C. Cost and insurance considerations

D. Different modes of administration and convenience

E. A, C, and D